Reslizumab - Biologic Drug Details

Summary for reslizumab

Tradenames:	1
High Confidence Patents:	2
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for reslizumab

Recent Clinical Trials for reslizumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
TEVA	Phase 2
National Jewish Health	Phase 2
Teva Pharmaceuticals USA	Phase 2

See all reslizumab clinical trials

Pharmacology for reslizumab

Mechanism of Action	Interleukin-5 Antagonists
Established Pharmacologic Class	Interleukin-5 Antagonist

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for reslizumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for reslizumab Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Teva Respiratory, Llc	CINQAIR	reslizumab	Injection	761033	6,056,957	2014-08-04	DrugPatentWatch analysis and company disclosures
Teva Respiratory, Llc	CINQAIR	reslizumab	Injection	761033	RE39548	2021-12-07	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for reslizumab Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Teva Respiratory, Llc	CINQAIR	reslizumab	Injection	761033	10,028,940	2037-03-16	Patent claims search
Teva Respiratory, Llc	CINQAIR	reslizumab	Injection	761033	10,111,968	2036-08-10	Patent claims search
Teva Respiratory, Llc	CINQAIR	reslizumab	Injection	761033	10,195,183	2037-08-14	Patent claims search
Teva Respiratory, Llc	CINQAIR	reslizumab	Injection	761033	10,195,211	2037-10-27	Patent claims search
Teva Respiratory, Llc	CINQAIR	reslizumab	Injection	761033	10,369,114	2037-05-24	Patent claims search
Teva Respiratory, Llc	CINQAIR	reslizumab	Injection	761033	10,435,452	2036-05-25	Patent claims search
Teva Respiratory, Llc	CINQAIR	reslizumab	Injection	761033	10,456,381	2038-06-20	Patent claims search

International Patents for reslizumab

Country	Patent Number	Estimated Expiration
Slovakia	282625
Australia	694783
Israel	114179
Austria	E264389
Canada	2192543
Slovakia	160096
Spain	2218546

Market Dynamics and Financial Trajectory for Reslizumab

Last updated: April 7, 2026

What is Reslizumab and its Approved Indication?

Reslizumab is a monoclonal antibody developed by Teva and approved by the FDA in 2016 for severe eosinophilic asthma. It targets interleukin-5 (IL-5), reducing eosinophil levels responsible for asthma inflammation.

Market Size and Growth Drivers

The global severe asthma market is valued at approximately $6.2 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 7.2% through 2029 [1]. IL-5 inhibitors, including reslizumab, account for about 28% of this market, reflecting a steady increase driven by the expanding patient population and enhanced biologic adoption.

Key drivers include:

• Growing prevalence of severe eosinophilic asthma, estimated at around 4-8% of all asthma cases.
• Increased healthcare provider awareness of biologics' efficacy.
• Broader label expansion opportunities into other eosinophil-driven diseases such as eosinophilic esophagitis and hypereosinophilic syndrome.
• Introduction of biosimilars and competitive biologics like mepolizumab and benralizumab.

Market Penetration and Competitive Landscape

Reslizumab competes with:

• Mepolizumab (Nucala): Market share of approximately 52%.
• Benralizumab (Fasenra): Holding around 35%.
• Others (e.g., early-stage biosimilars): Remaining share.

Reslizumab's market share remains limited due to factors including:

• Intravenous administration frequency (monthly infusion) versus subcutaneous options.
• Fewer approvals for additional indications.
• Limited physician familiarity relative to established competitors.

Financial Trajectory and Revenue Outlook

In 2022, reslizumab generated estimated sales of $150 million globally, primarily in North America and Europe. Market analysts forecast a CAGR of about 5% for reslizumab revenues through 2029, reaching approximately $230 million.

Factors influencing revenue include:

• Patent exclusivity extending through 2030, with potential for patent extensions.
• Market penetration rates of 20-25% among eligible severe eosinophilic asthma patients.
• Potential expansion into other indications could provide additional revenue streams.

Patents, Regulatory and Policy Environment

Reslizumab holds multiple patents protecting its formulation and use, with key patents expiring between 2029 and 2032. Regulatory actions or patent litigations could impact market exclusivity.

Pricing for reslizumab in the U.S. averages $5,300 per infusion, leading to high treatment costs (~$63,600 annually). Insurance coverage and payer policies influence market access.

Market Challenges and Risks

The primary risks include:

• Increasing competition from biosimilars and alternative biologics.
• Manufacturing costs for monoclonal antibodies.
• Evolving reimbursement policies globally.
• Shifts in clinical guidelines favoring subcutaneous biologics or oral therapies.

Strategic Considerations

Teva's strategy involves expanding indications, optimizing dosing regimens, and pursuing biosimilar development. Market expansion into pediatric populations, and rare eosinophil-related diseases could mitigate competitive pressures.

Key Financial Indicators

Metric	2022	2023 (Projected)	2029 (Forecast)
Revenue	$150 million	$160 million	$230 million
Market Share	10% in IL-5 inhibitor segment	Stable	Slight increase
CAGR	—	5%	5%

Summary

Reslizumab remains a niche but steady player in the biologic asthma segment. Its growth depends on expanding indications, competitive dynamics, and market penetration strategies. Patent protections and pricing policies form critical elements of its financial trajectory.

Key Takeaways

• Reslizumab addresses a segment with high unmet need but faces stiff competition.
• Revenue growth remains modest but stable; significant upside hinges on indication expansion.
• Patent protections extend to 2030, providing a market window before biosimilars may erode exclusivity.
• Pricing remains high, with reimbursement policies affecting access.
• Competitive landscape favors subcutaneous biologics, potentially limiting future growth.

FAQs

1. What distinguishes reslizumab from its competitors?
   Its intravenous administration differentiates it from subcutaneous options like mepolizumab and benralizumab, which may influence patient and provider preferences.

2. Are there ongoing trials to expand reslizumab’s indications?
   Yes, studies on eosinophilic esophagitis and hypereosinophilic syndrome are underway, which could diversify revenue sources.

3. How does pricing impact reslizumab’s market penetration?
   The high cost per infusion constrains broader adoption, especially in healthcare systems with strict reimbursement policies.

4. When do key patents expire?
   Patent protections extend into 2030, with some filings potentially providing extensions up to 2032.

5. What is the outlook for biosimilar competition?
   Biosimilar development is progressing, which could challenge reslizumab's market share post-2030 if approved and accepted.

---

References

[1] MarketResearch.com. (2022). Global Severe Asthma Market Report.
[2] EvaluatePharma. (2022). Biologicals Market Data.